Infectious Enteritis Treatment Market Size (2024 - 2029)

The infectious enteritis treatment market is projected to experience growth driven by an increase in cases related to irritable bowel syndrome and diarrhea, alongside intensified research and development efforts and a rise in FDA approvals for treatment drugs. The market's expansion was notably influenced by the COVID-19 pandemic, which heightened the demand for treatments due to gastrointestinal symptoms associated with the virus. Despite a current stabilization in growth due to reduced COVID-19 cases, the market is expected to maintain its growth trajectory. Initiatives by key market players, such as product launches and strategic partnerships, are anticipated to further enhance market expansion. However, challenges such as adverse treatment effects and limited awareness in developing regions may hinder market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Infectious Disease Drugs Research Infectious Enteritis Treatment Industry Market Size

Market Size of Infectious Enteritis Treatment Industry

Infectious Enteritis Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 4.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Infectious Enteritis Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Infectious Enteritis Treatment Market Analysis

The Infectious Enteritis Treatment market is anticipated to grow with a CAGR of nearly 4.9% during the forecast period.

The COVID-19 pandemic had a significant impact on the infectious enteritis market. According to an article published by Clinical Medicine in March 2022, acute gastrointestinal side effects were reported with COVID-19 infection and were estimated to affect around 17% of patients. According to an article published by the Harvard Gazette in November 2021, 60% of patients infected with SARS-CoV-2 also report gastrointestinal symptoms such as nausea, diarrhea, and stomach pain. With an increase in these intestinal enteritis symptoms, the demand for its treatment increase. Therefore, the increasing number of cases of COVID-19 further led to an increased number of cases of infectious enteritis, and thus the market witnessed considerable growth during the pandemic. However, the market is witnessing stabilized growth currently owing to the decrease in COVID-19 cases and the increase in these intestinal enteritis cases, and is expected to project a similar trend over the coming years as per the analysis.

Factors such as the rising population with irritable bowel syndrome (IBS) and diarrhea cases due to infectious enteritis and intensive research and development activities, and Increasing FDA approvals of infectious enteritis treatment drugs are expected to drive the growth of the market over the forecast period. For instance, according to an article published by the Middle East Journal of Digestive Diseases in July 2022, it was estimated that the incidence of IBS is 38.5 per 10,000 persons per year, and the prevalence has been reported to be 10-17% in the general population. Furthermore, according to an article published by BMC Medicine, in March 2022, IBS patients are subtyped based on bowel habit profile into diarrhea (IBS-D), constipation (IBS-C), mixed (IBS-M) or indeterminate, and approximately 10-20% of all cases develop after an episode of acute gastroenteritis. Thus, increase in the population with IBS and diarrhea cases due to infectious enteritis, the demand for its treatment increase, thereby driving the growth of the market over the forecast period.

Additionally, various initiatives taken by the key market players, such as product launches, mergers, acquisitions, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in November 2021, an interdisciplinary panel of infectious disease clinicians and public health experts led by the Center for Disease Dynamics, Economics & Policy (CDDEP) and the Africa CDC released the first edition of the African Antibiotic Treatment Guidelines for Common Bacterial Infections and Syndromes. Such an initiative is expected to drive the growth of the market.

The factors mentioned above are expected to drive the market's growth worldwide. However, several adverse effects associated with the treatment of infectious enteritis and a lack of awareness among people in developing countries are expected to restrain the growth of the studied market over the forecast period.

Infectious Enteritis Treatment Industry Segmentation

As per the scope of this report, enteritis refers to the inflammation of the small intestine. Infectious enteritis is the most common type and includes bacterial and viral enteritis. Eating or drinking contaminated food or water causes bacterial enteritis. Viral enteritis also occurs through eating or drinking contaminated food or water and after contact with someone who has the virus. Viral enteritis usually goes away within a few days. The Infectious Enteritis Treatment Market is Segmented By Route of Administration (Oral and Injectables), Drug Type (Antibiotics, Antivirals, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Route of Administration
Oral
Injectables
By Drug Type
Antibiotics
Antivirals
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Infectious Enteritis Treatment Market Size Summary

The infectious enteritis treatment market is poised for growth, driven by factors such as the rising incidence of irritable bowel syndrome and diarrhea cases linked to infectious enteritis. The market experienced significant expansion during the COVID-19 pandemic due to the increased gastrointestinal symptoms reported among infected individuals, which in turn heightened the demand for treatment. Currently, the market is stabilizing as COVID-19 cases decline, but the demand for infectious enteritis treatment remains strong. This demand is further bolstered by intensive research and development activities, increased FDA approvals for treatment drugs, and various initiatives by key market players, including product launches and strategic partnerships. However, challenges such as adverse treatment effects and limited awareness in developing regions may restrain market growth.

North America is expected to lead the infectious enteritis treatment market, primarily due to the high prevalence of pathogens and significant healthcare investments in the region. The United States, in particular, holds a substantial market share, supported by the presence of numerous pharmaceutical companies and ongoing product innovations. The market's competitive landscape is fragmented, with several global and regional players, including Actelion Pharmaceuticals, BioGaia, and Pfizer Inc., actively participating in market activities. These companies are engaged in new product developments and collaborations to enhance their market presence. Overall, the combination of increasing infection rates, strategic market initiatives, and regional dominance is anticipated to drive the market's growth over the forecast period.

Explore More

Infectious Enteritis Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 The rising population with IBS and diarrhoea cases due to infectious enteritis

      2. 1.2.2 Intensive research and development activities and Increasing FDA approvals of infectious enteritis treatment drugs

    3. 1.3 Market Restraints

      1. 1.3.1 Several adverse effects associated with the treatment of infectious enteritis

      2. 1.3.2 Lack of awareness among people in developing countries

    4. 1.4 Porter Five Forces

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Route of Administration

      1. 2.1.1 Oral

      2. 2.1.2 Injectables

    2. 2.2 By Drug Type

      1. 2.2.1 Antibiotics

      2. 2.2.2 Antivirals

      3. 2.2.3 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Infectious Enteritis Treatment Market Size FAQs

The Infectious Enteritis Treatment Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)

Novartis Pharmaceuticals , Teva Pharmaceuticals , Pfizer Inc., GlaxoSmithKline plc. and Mayne Pharma are the major companies operating in the Infectious Enteritis Treatment Market.

Infectious Enteritis Treatment Market Report Snapshots

Infectious Enteritis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)